Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients

dc.creatorWang, Zhenling
dc.creatorPan, Hailong
dc.creatorJiang, Boguang
dc.date.accessioned2020-09-30T20:05:50Z
dc.date.accessioned2022-09-23T18:10:39Z
dc.date.available2020-09-30T20:05:50Z
dc.date.available2022-09-23T18:10:39Z
dc.date.created2020-09-30T20:05:50Z
dc.identifier2059-3635
dc.identifierhttps://doi.org/10.1038/s41392-020-00306-4
dc.identifierhttp://hdl.handle.net/20.500.12010/14037
dc.identifierhttps://doi.org/10.1038/s41392-020-00306-4
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3496855
dc.description.abstractRecently, a paper published in Science by Hadjadj et al. reported that type I interferon (IFN) deficiency, could be a hallmark of severe coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe COVID-19 was also associated with a lymphocytopenia, persistent blood viral load, and an exacerbated inflammatory response (Fig. 1). These findings provide insights into the treatment of severe COVID-19 patients with type I IFN
dc.languageeng
dc.publisherSignal Transduction and Targeted Therapy
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectI IFN deficiency
dc.subjectImmunological characteristic
dc.subjectCOVID-19 patients
dc.titleType I IFN deficiency: an immunological characteristic of severe COVID-19 patients


Este ítem pertenece a la siguiente institución